MMSc

Inozyme Pharma Reports Full Year 2023 Financial Results and Provides Business Highlights

Retrieved on: 
Tuesday, March 12, 2024
Administration, Plasma, Kidney disease, ECTS, Massachusetts General Hospital, Pyrophosphate, PD, ASN, Partnership, Pharmacokinetics, Calciphylaxis, G&A, PROPEL, Doctor of Philosophy, Chemistry, Investment, PXE, Society, Pathology, Therapy, Safety, Research and development, ESKD, ENPP1, MMSc, Natural history, Pharmaceutical industry

BOSTON, March 12, 2024 (GLOBE NEWSWIRE) -- Inozyme Pharma, Inc. (Nasdaq: INZY) (“the Company” or “Inozyme”), a clinical-stage rare disease biopharmaceutical company developing novel therapeutics for the treatment of pathologic mineralization and intimal proliferation, today reported financial results for the full year ended December 31, 2023, and provided recent business highlights.

Key Points: 
  • “We believe we are well-positioned to continue to advance INZ-701 through several anticipated value-creating milestones in the year ahead,” said Douglas A. Treco, Ph.D., CEO of Inozyme Pharma.
  • Calciphylaxis represents a devastating condition characterized by pathologic mineralization and intimal proliferation.
  • Patients will receive 1.8 mg/kg of INZ-701 once weekly, coinciding with their hemodialysis treatment, for a total of 30 days.
  • The study’s primary endpoint will assess safety and change from baseline plasma PPi concentration, with secondary endpoints including PK and PD parameters.

AMERICAN SKIN ASSOCIATION ANNOUNCES NEW BOARD MEMBER JOSEPH F. MEROLA, MD, MMSc, FAAD, FACR

Retrieved on: 
Thursday, April 4, 2024
Cone Health Women's Hospital, Internal medicine, Patient, Skin, FAAD, Connective tissue, DSM-IV codes, Education, ASA, MDS, MMSc, Mass, Harvard Medical School, Associate, National Psoriasis Foundation, Psoriatic arthritis, Hospital, Public health, Atopic dermatitis, Dermatomyositis, Lupus, American Academy, Assessment, Management

NEW YORK, April 4, 2024 /PRNewswire/ -- American Skin Association (ASA) announced today that Joseph F. Merola, MD, MMSc, FAAD, FACR, will join its Board of Directors.

Key Points: 
  • NEW YORK, April 4, 2024 /PRNewswire/ -- American Skin Association (ASA) announced today that Joseph F. Merola, MD, MMSc, FAAD, FACR, will join its Board of Directors.
  • Distinguished Chair in Dermatology and is Professor at the Peter O'Donnell Jr. School of Public Health.
  • "We are proud to announce the addition of Dr. Joseph Merola to ASA's Board of Directors.
  • He was recently elected to the Board of the American Academy of Dermatology.

THE PANCREATIC CANCER ACTION NETWORK NAMES ANNA BERKENBLIT, MD, MMSc AS FIRST-EVER CHIEF SCIENTIFIC AND MEDICAL OFFICER

Retrieved on: 
Tuesday, April 2, 2024
Harvard Medical School, Health, Growth, ImmunoGen, Patient, Research, MD, MBA, Outline of health sciences, Pancreatic Cancer Action Network, Pancreatic cancer, Biomedicine, FDA, MMSc

LOS ANGELES, April 2, 2024 /PRNewswire/ -- The Pancreatic Cancer Action Network (PanCAN), the leading nonprofit in the fight against pancreatic cancer, announces Anna Berkenblit, MD, MMSc, a clinical oncologist and drug developer, as its first-ever chief scientific and medical officer.

Key Points: 
  • LOS ANGELES, April 2, 2024 /PRNewswire/ -- The Pancreatic Cancer Action Network (PanCAN), the leading nonprofit in the fight against pancreatic cancer, announces Anna Berkenblit, MD, MMSc, a clinical oncologist and drug developer, as its first-ever chief scientific and medical officer.
  • "And I'm really excited to join PanCAN to build on our scientific and medical initiatives to take PanCAN to the next phase of growth."
  • "We are honored to welcome Dr. Berkenblit to PanCAN as our first-ever chief scientific and medical officer.
  • She will serve as a thought leader for us in the pancreatic cancer scientific and medical community working with our external advisors and stakeholders," said Fleshman.

MoonLake announces significant improvements with Nanobody® sonelokimab over 24 weeks in active psoriatic arthritis (PsA) and other important updates at its R&D Day

Retrieved on: 
Sunday, March 10, 2024
Psoriatic arthritis, ACR, Doctor of Philosophy, Adalimumab, Skin, American College, Webcast, Moonlake, HS, Patient, Psoriasis, VELA, MMSc, ARGO, MIRA, EDT, Physician, Inflammation, Safety, Prognosis, Clinical trial, Ankylosing spondylitis, TNF, IL-17A, MDA, American Academy, EMA, Medical college, FDA, Food, Steroid, Prevalence, AAD, Event, Joint, PASI, Hidradenitis suppurativa, PSA, PPP, Disease, Porokeratosis, Medicine, Pharmaceutical industry

In addition, by week 24, over 80% and 60% of patients treated with sonelokimab achieved Psoriasis Area Severity Index (PASI) 90 and 100, respectively.

Key Points: 
  • In addition, by week 24, over 80% and 60% of patients treated with sonelokimab achieved Psoriasis Area Severity Index (PASI) 90 and 100, respectively.
  • Treatment with sonelokimab resulted in unprecedented improvements in composite scores that reflect responses in different domains simultaneously.
  • In all composite scores, sonelokimab showed 16-29 percentage point differences to the reference adalimumab arm, comparatively higher to competitors using the same reference arm.
  • The discontinuation rate of the second part of ARGO remained low at 5%, in line with other sonelokimab trials.

Largest study to date of high-dose methotrexate associated acute kidney injury supports the use of Voraxaze® (glucarpidase)

Retrieved on: 
Monday, December 11, 2023
MMSc, Hospital, AKI, Division, Cone Health Women's Hospital, Mortality, Neutropenia, SCR, Society, Odds ratio, Observational study, Acute kidney injury, Transaminase, MPH, Patient, Harvard Medical School, Nursing

West Conshohocken, PA, Dec. 11, 2023 (GLOBE NEWSWIRE) -- BTG Pharmaceuticals, a SERB company, announces the presentation of the largest study to date of patients with high-dose methotrexate (HDMTX) associated Acute Kidney Injury (AKI) treated with and without glucarpidase.

Key Points: 
  • West Conshohocken, PA, Dec. 11, 2023 (GLOBE NEWSWIRE) -- BTG Pharmaceuticals, a SERB company, announces the presentation of the largest study to date of patients with high-dose methotrexate (HDMTX) associated Acute Kidney Injury (AKI) treated with and without glucarpidase.
  • Among the 708 patients with HDMTX-AKI, 209 (29.5%) were treated with glucarpidase and 499 (70.5%) were not.
  • Treatment with glucarpidase was associated with a 2.41-fold higher adjusted odds of kidney recovery at hospital discharge (95% CI, 1.33–4.37) compared to those not treated with glucarpidase.
  • “This is the largest study to date of HDMTX-AKI,” said study author Dr. Shruti Gupta, MD, MPH, Director of Onconephrology in the Division of Renal Medicine, Brigham and Women's Hospital.

Galapagos to Host KOL Event on December 10, 2023, at 11:00 AM PST to discuss new data presented at ASH 2023

Retrieved on: 
Thursday, December 7, 2023
Associate, MMSc, Survival, Lymphoid leukemia, University of Antwerp, MD, Doctor of Philosophy, Galapagos NV, Euronext, Galápagos Islands, University, CLL, Oncology, PST, Patient, University of Chicago, Harvard Medical School, Clinical research, KOL, FACP, Management

Mechelen, Belgium; 6 December 2023, 22:01 CET; Galapagos NV (Euronext & NASDAQ: GLPG) today announced that it will host a Key Opinion Leader (KOL) event during the 65th ASH Annual Meeting & Exposition in San Diego, CA, on Sunday, December 10, 2023, from 11:00 am PST to 12:30 pm PST.

Key Points: 
  • Mechelen, Belgium; 6 December 2023, 22:01 CET; Galapagos NV (Euronext & NASDAQ: GLPG) today announced that it will host a Key Opinion Leader (KOL) event during the 65th ASH Annual Meeting & Exposition in San Diego, CA, on Sunday, December 10, 2023, from 11:00 am PST to 12:30 pm PST.
  • The in-person event will be held at the San Diego Marriott Gaslamp Quarter in the Presidio Ballroom B/C.
  • To register as an in-person attendee, please click here .
  • Galapagos leadership, including Paul Stoffels1, MD, CEO and Chairman, will provide updates on:
    A live question and answer will follow the formal presentations.

MEI Pharma Reports Clinical Data on Oral CDK9 Inhibitor Voruciclib at ASH2023

Retrieved on: 
Monday, December 11, 2023
Pharmaceutical, Health, Oncology, Clinical Trials, Pharmacokinetics, BCL2, Safety, Toxicity, Lymphoid leukemia, Acute myeloid leukemia, ASH, Cohort, Dana–Farber Cancer Institute, Cellular, Clinical research, Fatigue, Patient, CDK9, Division, DLT, Exposition, Index, Bone marrow, MD, Diarrhea, Nausea, MTD, Half-life, Transplant, AML, Biomarker, Anemia, MMSc, Infrared spectroscopy correlation table, Society, Failure, Poster, Venetoclax, Pharmaceutical industry, Vaccine, Lymphoma

The poster can be viewed on the MEI Pharma website here: https://meipharma.com/ash2023.html .

Key Points: 
  • The poster can be viewed on the MEI Pharma website here: https://meipharma.com/ash2023.html .
  • The second stage of the study is ongoing and is evaluating voruciclib in combination with venetoclax in patients with R/R AML.
  • The primary objectives of the study are to determine the safety and biologic effective dose of voruciclib monotherapy or voruciclib in combination with venetoclax.
  • Secondary objectives of the study include assessing the preliminary efficacy, pharmacokinetics, pharmacodynamics, and biomarkers of voruciclib monotherapy or voruciclib in combination with venetoclax.

Bio Ascend, a Vaniam Group Company, Reconvenes Inaugural Class of the "Academy of Next Wave of Investigators™" in CLL and NHL

Retrieved on: 
Monday, December 11, 2023
Leukemia Research, Associate, Research, Associate professor, SAN, Senior, Non-Hodgkin lymphoma, Weill Cornell Medicine, ASH, Leukemia, Emory University, Dana–Farber Cancer Institute, Clinical research, Chairperson, Patient, Faculty, Indolent lymphoma, Division, Mentorship, Chronic lymphocytic leukemia, University, Winship Cancer Institute, Oncology, Columbia University, US-China strategic engagement, MMSc, Society, NHL, MD Anderson Cancer Center, Innovation, CLL, Health, Next wave, Management, Hospital, Hematology, MD, Lymphoma

SAN DIEGO, Dec. 11, 2023 /PRNewswire/ -- Bio Ascend, Vaniam Group's medical education company, this past weekend reconvened the inaugural class of its Academy of Next Wave of Investigators™ at a networking reception during the 65th annual American Society of Hematology (ASH) annual meeting. These young clinical investigators are participating in a year-long opportunity to engage in live and virtual career development seminars with international thought leaders in the fields of chronic lymphocytic leukemia (CLL) and non-Hodgkin lymphoma (NHL).

Key Points: 
  • These young clinical investigators are participating in a year-long opportunity to engage in live and virtual career development seminars with international thought leaders in the fields of chronic lymphocytic leukemia (CLL) and non-Hodgkin lymphoma (NHL).
  • "This next generation of hematology leaders is at a critical moment in their promising careers," said Kraig Steubing, Head of Bio Ascend and Senior Vice President of Strategic Engagement at Vaniam Group.
  • We wholeheartedly thank the members of our inaugural class, our distinguished faculty, and the program's sponsors."
  • In the subsequent months, the early-career investigators have been meeting regularly with their assigned mentors, prior to reconvening in person at the ASH annual meeting this past weekend.

RevBio Awarded a $2 Million Follow-On NIH Grant to Reduce Opioid Use and Addiction with TETRANITE®

Retrieved on: 
Wednesday, October 25, 2023
Other Health, Research, Pharmaceutical, Medical Devices, Dental, Clinical Trials, Science, Biotechnology, Medical Supplies, FDA, Other Science, Health, NIDCR, Extraction (chemistry), MMSc, Alveolar osteitis, SBIR, Doctor of Philosophy, United, Multimedia, OUD, Tissue, Phase II, DRS, Tooth, NIH, United States drug overdose death rates and totals over time, Initiative, DMD, Regenerative medicine, Pain management, Addiction, Pain, Patient, Diagnosis, Bangladesh Technical Education Board, Pharmaceutical industry, Dentistry, Medical device

This product is intended to be used to fill extraction sites and mitigate post-operative pain following the removal of wisdom teeth.

Key Points: 
  • This product is intended to be used to fill extraction sites and mitigate post-operative pain following the removal of wisdom teeth.
  • This grant will fund the pre-clinical development of a dental bone graft formulation that will include the release of locally acting non-opioid pain medication.
  • Opioid use disorder (OUD) is a major problem in the US, accounting for 107,622 overdose deaths in 2021.
  • This also expands upon a Phase II SBIR grant ( 1R44DE032564-01 ) which RevBio received from the National Institute of Dental and Cranial Research (NIDCR).

New Study Published in Cardiovascular Digital Health Journal Shows Implicity's Algorithm Significantly Reduces AF Alert Burden in Remote Cardiac Monitoring

Retrieved on: 
Tuesday, October 24, 2023
RPM, Stroke, National Association Medical Staff Services, European Heart Journal, Trial of the century, Incidence, MMSc, ESC, Physician, Atrial fibrillation, Arrhythmia, European Society of Cardiology, Doctor of Philosophy, Classification, AF, CI-966, Patient, Medtronic, Heart failure, Fatigue, Medical device, Nursing, MD, Cardiology, Implication (information science)

CAMBRIDGE, Mass., Oct. 24, 2023 /PRNewswire/ -- Implicity, a leader in remote patient monitoring (RPM) and cardiac data management solutions, today announced the results of a clinical study published in the Cardiovascular Digital Health Journal.

Key Points: 
  • CAMBRIDGE, Mass., Oct. 24, 2023 /PRNewswire/ -- Implicity , a leader in remote patient monitoring (RPM) and cardiac data management solutions, today announced the results of a clinical study published in the Cardiovascular Digital Health Journal.
  • "For a patient with AF who is already anticoagulated, a single AF episode isn't as important as established patterns or occurrences associated with arrhythmia progression and patient outcomes.
  • Results showed the algorithm broke down 67,883 AF burden-related alerts into 9,728 (14.3%) clinically relevant AF events, according to the European Society of Cardiology classification.
  • Implicity's algorithm works with any device that collects atrial burden trends data and can classify the following scenarios in line with ESC recommendations: